相似文献
1
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase.
Eur Respir J. 2021 Jul 1;58(1). doi: 10.1183/13993003.00956-2021. Print 2021 Jul.
2
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?
Infection. 2021 Oct;49(5):1071-1074. doi: 10.1007/s15010-021-01658-x. Epub 2021 Jul 21.
3
Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):e77-e78. doi: 10.1093/ehjcvp/pvab036.
4
Deep vein thrombosis more than two weeks after vaccination against COVID-19.
Tidsskr Nor Laegeforen. 2021 Apr 28;141. doi: 10.4045/tidsskr.21.0274. Print 2021 Apr 29.
5
The International Cerebral Venous Thrombosis Consortium report on cerebral venous thrombosis following vaccination against SARS-CoV-2.
Eur J Neurol. 2021 Nov;28(11):3543-3544. doi: 10.1111/ene.15085. Epub 2021 Sep 14.
6
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination.
Thromb Res. 2021 Jun;202:182-183. doi: 10.1016/j.thromres.2021.04.001. Epub 2021 Apr 8.
7
Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19.
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.11.019. Epub 2020 Nov 20.
8
COVID-19 vaccination prevents venous thrombosis in patients with SARS-CoV-2 infection and thereafter.
Blood Coagul Fibrinolysis. 2024 Jul 1;35(5):225-226. doi: 10.1097/MBC.0000000000001310. Epub 2024 Jul 5.
9
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis: Response from original authors Pola et al.
J Thromb Haemost. 2020 Nov;18(11):3110-3111. doi: 10.1111/jth.15089.
10
Cerebral Venous Thrombosis following COVID-19 Vaccination.
J Stroke Cerebrovasc Dis. 2021 Oct;30(10):105866. doi: 10.1016/j.jstrokecerebrovasdis.2021.105866. Epub 2021 May 10.
引用本文的文献
1
The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Korean J Intern Med. 2025 Sep;40(5):801-812. doi: 10.3904/kjim.2025.056. Epub 2025 Aug 26.
2
Vaccines Against Urban Epidemic Arboviruses: The State of the Art.
Viruses. 2025 Mar 6;17(3):382. doi: 10.3390/v17030382.
3
Relevance of anti-platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic.
Res Pract Thromb Haemost. 2025 Feb 9;9(1):102701. doi: 10.1016/j.rpth.2025.102701. eCollection 2025 Jan.
4
Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism.
J Infect Dis. 2025 Feb 20;231(2):378-385. doi: 10.1093/infdis/jiae502.
5
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.
Int J Mol Sci. 2024 Jul 26;25(15):8155. doi: 10.3390/ijms25158155.
6
Case report: A case of unilateral combined central retinal vein occlusion, incomplete central retinal artery occlusion, and papillitis following a third dose of COVID-19 vaccination.
Front Ophthalmol (Lausanne). 2024 Feb 23;4:1352962. doi: 10.3389/fopht.2024.1352962. eCollection 2024.
7
Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase).
BMJ Open Respir Res. 2023 Dec 11;10(1):e001992. doi: 10.1136/bmjresp-2023-001992.
8
Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations.
TH Open. 2023 Dec 4;7(4):e303-e308. doi: 10.1055/a-2183-5269. eCollection 2023 Oct.
9
ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review.
Adv Pharm Bull. 2023 Nov;13(4):723-735. doi: 10.34172/apb.2023.081. Epub 2023 Apr 29.
10
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination.
Biomedicines. 2023 Oct 17;11(10):2813. doi: 10.3390/biomedicines11102813.
本文引用的文献
1
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
2
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
N Engl J Med. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882. Epub 2021 Apr 9.
3
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission.
Eur Respir J. 2021 Jul 20;58(1). doi: 10.1183/13993003.00116-2021. Print 2021 Jul.
4
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
5
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
6
Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study.
J Am Heart Assoc. 2021 Apr 20;10(8):e018624. doi: 10.1161/JAHA.120.018624. Epub 2021 Feb 8.
7
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.
Angiogenesis. 2021 Aug;24(3):505-517. doi: 10.1007/s10456-020-09762-6. Epub 2021 Jan 15.
8
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01634-2020. Print 2020 Jul.
Zotero 插件